Neurobiological Technologies, Inc.

— Leo Cancer Care’s upright patient positioning system to be integrated into Neutron Therapeutics’ nuBeam® therapy platform — — Companies will announce partnership at the Annual Meeting of the American Society for Radiation Oncology (ASTRO) — NEW YORK & SAN DIEGO--(BUSINESS WIRE)-- Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics, a leading developer of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced an exclusive, strategic partnership with Leo Cancer Care, a company developing upright patient positioning systems for radiation therapy. The goal of the partnership between the three companies is to expand BNCT as a potential treatment for different types of cancer. This press release features multimedia. View the full release here: Leo Cancer Care’s upright patient positioning system will be integrated into Neutron’s nuBeam® therapy platform, which is a compact, in-hospital neutron source designed to replace legacy nuclear reactors for BNCT. The companies will speak about their initiative today at 3:45 p.m. PT at booth #4207 at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), which is being held in San Diego. “The incorporation of Leo’s upright patient positioning system with Neutron Therapeutics’ nuBeam® neutron accelerator has the potential to increase the versatility and impact of BNCT for patients, physicians, treatment centers and the overall healthcare system,” said Dave Greenwald, Ph.D., chief executive officer of Aviko and vice president of business development at Deerfield. “This strategic partnership is an important moment for our three companies as we work together to build a complete suite of both therapies and technologies that have the potential to provide boron neutron capture therapy to patients in need.” The BNCT treatment under development by Aviko Radiopharmaceuticals and Neutron Therapeutics involves an investigational non-toxic boron medicine that is designed to accumulate in cancer cells. The boron medicine remains inert until it is irradiated by low-energy neutrons at the site of the tumor, releasing alpha particles that destroy cancerous cells. Positioning the patient in relation to the neutron beam is important to support patient safety and the clinical activity of BNCT. Traditionally, patients have been supine when receiving BNCT and other forms of radiation therapy. Leo Cancer Care has developed an upright patient positioning system that is designed to allow for greater efficiency and precision when delivering neutrons to the tumor compared to supine positioning systems. “With our upright patient positioning system, all areas of the body can be positioned close to the neutron source to receive a precise delivery of neutrons at the site of the tumor,” said Stephen Towe, chief executive officer of Leo Cancer Care. “We believe that upright radiotherapy results in a better experience for patients compared to supine radiotherapy. We are excited to collaborate with Aviko and Neutron as we advance BNCT to potentially treat a variety of solid tumors.” Disclaimer The products being developed by Aviko Radiopharmaceuticals, Neutron Therapeutics and Leo Cancer Care are in development and are limited to investigational use. These products have not received marketing authorization from the FDA and are not commercially available. About Boron Neutron Capture Therapy (BNCT) Boron neutron capture therapy (BNCT) is a precision medicine approach that is being advanced to treat cancer by destroying cancerous cells while minimizing the impact to surrounding healthy tissues. BNCT uses a non-toxic boron medicine that is administered to the patient. The medicine is designed to accumulate in cancer cells while being quickly cleared from normal tissues in the body. The boron medicine remains inert until it is irradiated at the site of the tumor with low-energy neutrons, releasing alpha particles that can destroy cancerous cells. BNCT may also have applications in treating other diseases. Currently there are 21 BNCT clinics worldwide, primarily in Asia and Europe. About Leo Cancer Care Leo Cancer Care is dedicated to being the more human way to deliver radiation therapy. Their family of world class radiation therapy solutions is designed to provide a streamlined and efficient treatment, whilst making the patient feel in control and hopeful. Leo Cancer Care has been built on research from across the globe showing the clinical benefits of upright patient positioning. Combining this with a shift from machine rotation to patient rotation, Leo Cancer Care is set to make radiation therapy more accessible than ever before. To find out more about Leo Cancer Care visit: About Neutron Therapeutics Neutron Therapeutics is a leading developer of accelerator-based boron neutron capture therapy (BNCT) systems for use in targeted radiation therapy of solid tumors. Neutron Therapeutics’ flagship product, the nuBeam® therapy platform, is a compact, in-hospital neutron source designed to replace legacy nuclear reactors for BNCT. The nuBeam® system offers a higher neutron flux than competing systems and is the only BNCT system to adhere to all International Atomic Energy Agency standards. About Aviko Radiopharmaceuticals Aviko Radiopharmaceuticals is a privately held biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT) to treat a wide variety of cancers. Aviko’s innovative compounds are designed to improve the efficacy of BNCT by targeting and delivering boron to cancer cells with precision. Together with their partners, Aviko is advancing BNCT as a convenient treatment modality for patients. Founded by Deerfield Management, Aviko is based at Cure., a healthcare innovation campus in New York City. Follow Aviko on LinkedIn and Twitter.

AdisInsight是Springer旗下面向药物研发、疾病治疗和决策的数据库。1. QurAlis与Unlearn公司合作，利用生成式人工智能技术加速ALS临床试验QurAlis与 Unlearn 达成合作，利用数字孪生技术平台加快和优化肌萎缩性脊髓侧索硬化症（ALS）的临床项目。该合作旨在减少 QRL 201和 QRL 101临床试验中的变异性并提高研究能力。Unlearn 的专利机器学习模型是基于现有的临床数据进行训练的。经过验证后，这些模型将根据TwinRCT中每位入组患者的基线数据创建数字孪生，无论其随机化分配如何。2. SK生物科学和Peter Doherty研究所合作开展流感疫苗研究SK生物科学（SK bioscience）和Peter Doherty感染与免疫研究所达成合作，共同开发首个基于细胞培养的四价流感疫苗。根据这项合作协议，SK生物科学和Peter Doherty研究所将共同支持和推进流感生物学、疫苗和抗病毒药物的研究。该计划将包括测试抗流感化合物以确定新的抗病毒药物，在该地区中低收入国家进行能力建设，以及开发新的流感疫苗平台。3. 信达生物和荣昌生物在中国合作开展信迪利单抗和新型ADC的联合治疗信达生物制药公司（Innovent Biologics）与荣昌生物（RemeGen）达成研究和临床试验合作，在中国开展信迪利单抗（Sintilimab）注射剂与荣昌生物新型ADC（抗体药物偶联物）候选药物联合治疗实体瘤的研究。荣昌生物的RC 88和RC 108将与信迪利单抗注射剂进行联合评估。根据协议条款，信达将向荣昌生物提供信迪利单抗，以开展I/IIa期试验，评估与RC 88或RC 108联合治疗中国晚期实体瘤患者的抗肿瘤活性和安全性。4. Prime Medicine和Cimeio Therapeutics合作开发更安全、更有效的干细胞移植手术Prime Medicine 公司与 Cimeio Therapeutics 公司达成研发协议，通过结合各自的技术（即 Prime Medicine 公司的先导编辑技术（ Prime Editing） 平台和 Cimeio 公司的SCIP技术（Shielded Cell and Immunotherapy Pairs）平台） ，提高造血干细胞移植的安全性和有效性，来治疗遗传性疾病、急性髓性白血病（AML）和骨髓增生异常综合征（MDS）。根据协议条款，Prime Medicine 公司将为 Cimeio 公司的 CD117屏蔽变体开发一种先导编辑器，然后由两家公司进行评估。CD117是一种在正常造血干细胞和白血病细胞上表达的受体酪氨酸激酶，因此对于需要干细胞移植的患者或者需要新治疗方案的 AML 或 MDS 患者来说，是一个有吸引力的抗体调理疗法靶点。5. Virpax制药公司与NINDS合作，评估其用于治疗癫痫的大麻二酚候选产品Virpax Pharmaceuticals宣布已与美国国家神经疾病和中风研究所（NINDS）签订了合作研发协议（CRADA）。该研究所属于美国国立卫生研究院（NIH）转化研究部，负责开展和资助大脑和神经系统疾病的研究。Virpax将与癫痫治疗筛查计划（ETSP）合作，该计划的任务是鉴定新型药物，以满足癫痫领域尚未满足的医疗需求，包括确定专注于解决耐药性癫痫、疾病预防和治疗的下一代产品。根据CRADA，NINDS ETSP将评估大麻二酚（NobrXiol）候选产品。6. 阿斯利康与上海珂阑医药合作治疗高胆固醇血症阿斯利康和珂阑医药（Cholesgen）达成研发协议，开发治疗高胆固醇血症和相关代谢疾病的药物。这项协议为期三年，双方将开展联合研究，验证基因药物靶点，并推动治疗分子进入临床开发阶段。对于阿斯利康公司提名进入临床开发阶段的每一种合格候选药物，Cholesgen公司都将获得初始款项和预先确定的许可证。联合研究团队将进行靶点鉴定工作，阿斯利康则将进一步开展临床开发。7. 安斯泰来和睿跃生物合作开发靶向蛋白质降解剂安斯泰来制药公司和睿跃生物（Cullgen）达成了合作和独家期权协议，通过将 Cullgen 公司专有的 uSMITETM 靶向蛋白质降解平台（以新型E3配体为特色）与安斯泰来的药物发现能力相结合，探索多种创新的蛋白质降解剂。根据协议条款，两家公司将合作进行联合研究，以确定临床开发候选药物。安斯泰来将拥有在研究活动中确定的蛋白降解剂临床开发和商业化的独家许可权。在临床开发的初始阶段，Cullgen将有权平等分担成本、利润和亏损，并在美国共同推广重点项目的合作产品， Cullgen公司此前将这一产品确定为用于治疗乳腺癌和其它实体瘤的细胞周期蛋白降解剂。8. EvolveImmune Therapeutics与肯尼迪风湿病学研究所合作，评估其专有的共刺激 T 细胞参与平台的分子作用机制免疫肿瘤学公司EvolveImmune Therapeutics与牛津大学肯尼迪风湿病学研究所达成了一项研究合作，以评估EvolveImmune公司专有的共刺激T细胞参与平台的分子作用机制。该项目将利用牛津大学开发的支持性脂质双层（SLB）技术EVOLVE，该技术能够重现精准的分子相互作用，包括肿瘤细胞膜和细胞溶解性 T 细胞之间在体外形成的界面（称为免疫突触）。EvolveImmune-Oxford 将仔细评估与传统 CD3双特异性抗体药物相比，EVOLVE 对免疫突触行为的动力学、突触内的分子变化和 T 细胞功能反应的影响。9. Future Fields与 Jenthera Therapeutics合作开发一种高效节约可持续的以CRISPR 为基础的新型癌症疗法Future Fields是一家开创性的生物技术公司，与Jenthera Therapeutics合作开发一种新型蛋白质，可用于工业生产的一种首创抗癌蛋白。Future Fields的专有平台（EntoEngine™）将使用果蝇大规模生产这种正在开发的新型蛋白质，比传统的生物制药生产技术更可持续和更具成本效益。而基因编辑公司Jenthera Therapeutics则开发了一种方法，可以直接在体内提供安全有效的CRISPR形式。10. Aviko Radiopharmaceuticals和Neutron Therapeutics合作推进用于治疗癌症的硼中子捕获疗法Aviko Radiopharmaceuticals与Neutron Therapeutics建立了战略伙伴关系，致力于开发硼中子俘获疗法（BNCT）。根据这项协议，两家公司将在美国建立第一个 BNCT 治疗中心，并通过与一流的学术医疗中心合作，建立更多的 BNCT 设施。这一战略伙伴关系结合了 Aviko 公司在药物开发方面的专业知识和 Neutron 公司业界领先的中子输送技术，目标是改善各种癌症患者的治疗结果。11. 拜耳取得Acuitas公司的脂质纳米颗粒技术支持，升级其基因疗法项目拜耳及其旗下基因疗法公司Asklepios BioPharmaceutical（AskBio）将获得Acuitas公司的高效力可电离脂质技术和脂质纳米颗粒（LNP）载体，用于开发高效、靶向和瞬时向肝脏递送基因编辑RNA成分的技术。市场成熟度和经证实的生产可扩张性将为该项目的发展推波助澜，并可能加速拜耳与AskBio的首个体内基因编辑项目进入临床。AdisInsight数据库试用申请AdisInsight是以科学数据为依据，面向药物研发、疾病治疗和决策的数据库。信息包括药物的疗效、安全性、研发者、交易和专利，以及药物多久能上市等，为您提供全球药物治疗有力的最新证据，帮助用户始终处于研究的前沿。如您对AdisInsight数据库感兴趣，欢迎推荐您所在机构申请试用。扫码申请试用AdisInsight向上滑动，回顾更多重大事件12. Samyang Biopharmaceuticals与LG化学合作开发新型mRNA抗癌疗法Samyang Biopharmaceuticals与LG化学就开发mRNA抗癌创新疗法达成战略合作协议。根据协议条款，Samyang会授予LG化学“NanoReady”技术的非独家许可权，并负责向其提供这项技术的关键部件。LG化学将利用“NanoReady”技术开发具有最大疗效的mRNA抗癌创新疗法。为此，LG化学需要支付一笔预付款，并在达成开发目标后支付一系列阶段性付款。13. Sygnature Discovery与大熊制药就新药发现与开发达成合作大熊制药与Sygnature Discovery达成研究合作，以扩大其在新药开发方面的全球开放创新生态。根据协议条款，Sygnature Discovery将提供其专有的基于片段的药物发现（FBDD）和虚拟高通量筛选（vHTS）技术，加速大熊制药用以治疗自身免疫性疾病的新药发现。此外，大熊制药将获得蛋白质科学和晶体学方面的支持，以验证并确保作用机制的安全性。通过本次合作，大熊制药希望将其药物发现范围扩大到蛋白质相互作用（PPI）领域，继续落实新一代药物发现战略。14. Argenx与Genmab合作推进免疫学和肿瘤学领域的抗体治疗Argenx与Genmab达成合作协议，以共同发现、开发并商业化新型治疗性抗体，应用于免疫学及肿瘤学治疗领域。这项为期多年的合作将利用两家公司的抗体工程专长和疾病生物学知识，加速新型治疗性候选抗体的识别与开发，旨在解决免疫学和癌症领域亟需满足的患者需求。根据该协议，Argenx与Genmab各自将获得对方的专有抗体技术，以推进针对不同疾病靶点的先导候选抗体识别。根据协议条款，Argenx与Genmab将共同发现、开发并商业化本次合作所得产品，同时平分成本和任何潜在的未来收益。本次合作最初将专注于两个靶点（分属免疫学和癌症领域），并有可能扩展到更多靶点。15. Flare Therapeutics与Caris Life Sciences合作推进其精准肿瘤学项目Caris Life Sciences与Flare Therapeutics宣布达成一项多年期的战略合作，以通过先进的分子谱分析指导患者选择，将Flare的五个治疗项目中的精准医疗方法加速推进至临床试验。本次合作将利用Caris全面的分子组织和液体检测服务，对Flare的临床试验患者进行全外显子测序和全转录组测序，同时应用Caris的数据和分析工具，改善未来的临床试验入组项目并增强伴随诊断能力，从而强化Flare对纵向研究的承诺。16. Xenetic Biosciences与斯克里普斯研究所合作推进其全身DNase项目Xenetic Biosciences与斯克里普斯研究所达成研究资助与选择权协议，以推进其全身DNase项目和DNase-armored CAR T项目。根据协议条款，除了推进Xenetic现有的知识产权外，Xenetic还有权获得本次DNase研究项目所得的任何新知识产权的独家许可。17. Lygenesis与Imagine Pharma合作开发1型糖尿病的新型细胞疗法Lygenesis与Imagine Pharma达成联合研究合作协议，为1型糖尿病患者开发新型细胞疗法。根据协议条款，本次研究合作将利用Imagine Pharma的1型糖尿病活化胰岛祖细胞（T1D AIPCs）和LyGenesis的异体细胞治疗平台，以开发1型糖尿病疗法。18. Biotheryx与Incyte合作开发针对肿瘤学新靶点的蛋白降解剂Biotheryx与Incyte达成研究合作与许可协议，以发现并开发针对肿瘤学新靶点的蛋白降解剂。根据协议条款，Biotheryx将利用其独特的PRODEGY平台，针对多个历史上不可成药的肿瘤学靶点，识别并初步开发分子胶降解剂。Biotheryx最初将收到一笔700万美元的技术使用费，外加600万美元的潜在研发经费，用于支付与合作相关的成本。此外，Biotheryx还有资格获得高达3.47亿美元的潜在获批与商业化阶段性付款，以及基于全球产品净销售额的梯度专利使用费。Incyte将全权负责PRODEGY平台所发现的分子胶降解剂的进一步开发和商业化。19. JCR Pharmaceuticals与阿斯利康罕见病业务子公司Alexion合作开发神经退行性疾病创新疗法JCR Pharmaceuticals与阿斯利康罕见病业务子公司Alexion达成研究合作、选择权与许可协议，以利用JCR专有的血脑屏障穿透技术J-Brain Cargo®，开发一种未公开的初始治疗性分子，用于治疗一种神经退行性疾病。根据协议条款，两家公司将把J-Brain Cargo®技术与一种未公开的效应分子相结合，研发新的疗法。在研究期间，Alexion有权选择提名针对未公开的适应症的、额外的治疗性候选蛋白。20. Innate Pharma与武田制药签署许可协议，开发用于治疗乳糜泻的ADCInnate Pharma与武田制药达成许可协议，授予武田制药使用一组选定的Innate抗体，针对一个未公开的靶点开发抗体药物偶联物（ADC）的独家研发权利，主要针对乳糜泻。根据协议条款，Innate Pharma将获得一笔500万美元的预付款，如果在协议期间实现了所有的阶段性目标，Innate Pharma还有资格获得高达4.1亿美元的开发、获批和商业化阶段性付款，以及基于本次合作所得商业产品潜在净销售额的专利使用费。武田制药将负责任何基于许可抗体的潜在产品的开发、生产和商业化。21. IPA的子公司Talem Therapeutics与Astellas的Xyphos Biosciences达成独家研究合作与许可选择权协议AI驱动的生物治疗研究和技术公司IPA（ImmunoPrecise Antibodies）的子公司——Talem Therapeutics——与Xyphos Biosciences（安斯泰来的全资子公司）达成研究合作与独家许可选择权协议。根据协议条款，两家公司将共同开展研究，以识别并优化专有的LENSai技术生成的、靶向肿瘤微环境（TME）中一个未公开靶点的抗体，作为潜在的治疗开发候选物。22. 莫德纳与Gandeeva合作探索AI驱动的冷冻电镜平台在其项目中的应用Gandeeva Therapeutics与莫德纳达成研究合作协议，以探索Gandeeva的差异化技术平台在莫德纳一个项目中的应用。根据协议条款，Gandeeva Therapeutics和莫德纳将研究并验证前者专有的冷冻电镜（cryo-EM）平台在莫德纳一个未公开靶点上的应用。为此，Gandeeva Therapeutics将获得研究付款。23. Onconova Therapeutics与Pangea Biomed合作识别对rigosertib有反应的生物标志物Onconova Therapeutics与Pangea Biomed达成研发协议，以识别对rigosertib有反应的生物标志物。根据该协议，本次合作将利用Pangea Biomed专有的算法平台ENLIGHT，旨在识别对Onconova专有的试验用候选产品rigosertib有反应的生物标志物。24. 成都先导与Arase Therapeutics合作开发抗癌疗法成都先导宣布与ARase Therapeutics, Inc.（"ARase"）达成研究协议。ARase是一家生物技术公司，致力于开发靶向ADP-核糖基水解酶的创新疗法，此类酶是作用于癌症应激通路的新靶点。成都先导将利用其DNA编码化合物库（DEL）技术平台（用于DEL的设计、合成和筛选），发现针对ARase的已验证的肿瘤学靶点的新型抑制剂，并在hit-to-lead优化到临床前开发阶段向ARase提供支持。25. Next&Bio与新加坡癌症科学研究所合作利用癌症类器官开发新型精准医学疗法Next&Bio与新加坡国立大学（NUS）的新加坡癌症科学研究院（CSI Singapore）签署谅解备忘录（MOU），就利用癌症类器官开发新型精准医学疗法建立合作。根据备忘录，CSI Singapore与Next&Bio将就建立联合癌症类器官实验室并开展联合项目进行商讨。Next&Bio有望利用其类器官培养技术，与CSI Singapore的专家合作创建一个类器官库，以供基于患者来源肿瘤类器官的研究项目使用，并用于建立患者特异性药物评价平台。26. 拜耳与Bicycle Therapeutics合作为未公开的肿瘤学靶点开发双环肽2023年5月，拜耳与Bicycle达成战略合作协议，以针对多个双方商定的肿瘤学靶点，发现、开发、生产和商业化Bicycle放射性偶联药物。根据协议条款，拜耳和Bicycle将为多个肿瘤学靶点合作开发双环肽。Bicycle将利用其专有的噬菌体平台来发现并开发双环肽，拜耳将负责并全额负担所有后续的临床前和临床开发、生产和商业化活动。27. 安斯泰来与索尼合作开发肿瘤学领域的新型ADC平台索尼与安斯泰来达成合作研究协议，以共同探索并开发肿瘤学领域的新型抗体偶联药物（ADC）平台。根据该协议，索尼与安斯泰来将利用前者独特的聚合物材料“KIRAVIA™ Backbone”，合作开发并优化新型ADC平台，以实现高药物-抗体比（DAR），并将抗癌药物有效递送到靶细胞。安斯泰来还将负责为候选开发药物开展非临床试验。此外，为扩展其药物发现平台，两家公司同意探索研究合作新领域，通过结合索尼的先进技术与安斯泰来的制药能力来创造新的价值。28. Chinook与Ionis合作开发用于治疗罕见的严重慢性肾病的ASO疗法Chinook Therapeutics与Ionis Pharmaceuticals达成合作协议，以针对一种存在巨大医疗需求且亟需满足的、罕见的严重慢性肾病，发现、开发并商业化一种反义寡核苷酸（ASO）疗法。两家公司将利用Chinook的精准医学方法和肾脏学领域的深厚专长，以及Ionis在RNA靶向治疗方面的广泛专业知识。根据协议条款，Chinook将向Ionis支付一笔预付款（金额未公开），以及潜在的开发和获批阶段性付款和专利使用费。Ionis将负责IND之前的毒理学研究，Chinook将负责临床开发与商业化。29. 大睿生物与康诺亚合作开发用于治疗肾小球肾炎的siRNA疗法大睿生物与康诺亚宣布达成合作，以共同发现并开发用于治疗肾小球肾炎的siRNA疗法。本次合作将利用双方的科学和技术专长，并将以大睿生物针对肝脏和肝外组织的专有RNAi平台为基础。根据合作条款，大睿生物将使用专有的RAZOR™平台，来发现和寻找针对肾小球肾炎相关新靶点的siRNA先导化合物，康诺亚将贡献临床研究和转化医学专业知识和能力。双方已达成损益协议，将在全球范围内进一步共同开发并商业化从这些发现工作中产生的候选治疗产品。30. 优时比与Ariceum就免疫相关性疾病和癌症治疗达成合作Ariceum Therapeutics与优时比签署独家战略研究合作协议，以发现并开发用于治疗实体瘤和免疫相关性疾病的新型全身靶向放射性药物。根据协议条款，优时比与Ariceum将利用彼此专有的技术平台，发现肽-放射性同位素偶联物，以作为免疫相关性疾病和癌症的潜在疗法。Ariceum将获得优时比的专长，以利用其mRNA展示技术平台ExtremeDiversity™来发现新的合成大环肽。而优时比将受益于Ariceum在放射化学和标记技术领域的专长，更好地探索这项技术在发现免疫相关性疾病的高度差异化治疗产品方面的潜力。在本次研究合作期间，两家公司有机会探索多个靶点。31. 山德士与Just-Evotec合作开发并生产多种生物类似药山德士与Just - Evotec Biologics就多种生物类似药的开发与生产达成协议，协议中包含扩展选择权。根据协议条款，山德士获得Just - Evotec Biologics专有的全集成原料药开发与持续生产AI技术平台使用权。通过本次合作，山德士现有的管线将由15+扩展到24个，早期生物类似药管线也将得到继续开发。32. PharmAla Biotech与Vitura Health在澳大利亚成立致幻剂合资企业PharmAla Biotech与Vitura Health宣布成立一家50:50的合资企业Cortexa。Cortexa将提供MDMA和赛洛西宾产品，以供授权医师的临床处方使用，并用于学者和商业研究人员的临床试验。Cortexa将获得PharmAla的制造技术与知识产权许可，在GMP条件下实现MDMA和赛洛西宾产品的高效生产。版权声明：本文由施普林格∙自然上海办公室负责编译。中文内容仅供参考，一切内容以英文原版为准。欢迎转发本文至朋友圈，如需转载，请联系 China@nature.com。© 2023 Springer Nature Limited. All Rights Reserved//点击“阅读原文”了解产品详情并获取相关资源

—Partnership aligns efforts to establish first boron neutron capture therapy treatment center in the U.S.— —Companies intend to collaborate with academic medical centers to establish additional BNCT facilities— NEW YORK & BOSTON--(BUSINESS WIRE)-- Aviko Radiopharmaceuticals, a Deerfield Management-founded biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT), and Neutron Therapeutics, the leading provider of accelerator-based neutron systems for targeted radiation therapy of solid tumors, today announced the formation of a strategic partnership to advance BNCT to treat cancer. The partnership aligns the companies’ efforts to build the first BNCT treatment center in the United States and to establish additional BNCT facilities through collaborations with premier academic medical centers. This press release features multimedia. View the full release here: “To bring BNCT to patients in need, it’s critical to foster collaboration among key stakeholders who are working to advance this precision medicine modality,” said Dave Greenwald, Ph.D., chief executive officer of Aviko and vice president of business development at Deerfield. “This strategic partnership brings together Aviko’s expertise in drug development and Neutron’s industry-leading neutron delivery technology with the goal of improving outcomes for patients with a variety of cancers.” BNCT involves a non-toxic boron medicine that is designed to accumulate in cancer cells. The boron medicine remains inert until it is irradiated by safe, low-energy neutrons at the site of the tumor, releasing alpha particles that destroy cancerous cells. Aviko has developed a pipeline of boron medicines that exhibit properties to enable effective BNCT, including high tumor selectivity. Neutron’s nuBeam® system is a comprehensive BNCT treatment suite with an accelerator that produces the highest neutron flux available in the clinical setting, leading to potentially shorter treatment times and improved patient experience. “BNCT has demonstrated the ability to eradicate tumors in as few as one or two treatments, while minimizing damage to healthy tissue,” said Elizabeth Reczek, Ph.D., chief executive officer of Neutron Therapeutics. “We’re thrilled to partner with Aviko in our efforts to expand BNCT as a treatment modality in the U.S. and globally.” Neutron has installed its nuBeam® system at Helsinki University Hospital in Helsinki, Finland, and at Shonan Kamakura General Hospital in Kamakura City, Kanagawa prefecture, Japan. “Recent innovations related to neutron acceleration have expanded the opportunities for BNCT to be used in a wide range of medical centers,” said Bill Buckley, co-founder of Neutron Therapeutics and founder of New Zealand-based Buckley Systems. “This partnership is an example of how two companies can collaborate to advance a promising therapy to help patients who are in need of more effective treatment options.” Ted Smick, chief technology officer and co-founder of Neutron Therapeutics, added: “Together, Aviko and Neutron Therapeutics offer a complete solution for BNCT, enabling more medical centers to provide this powerful new treatment to patients.” About Boron Neutron Capture Therapy (BNCT) Boron neutron capture therapy (BNCT) is a precision medicine approach that is being advanced to treat cancer by destroying cancerous cells while minimizing the impact to surrounding healthy tissues. BNCT uses a non-toxic boron medicine that is administered to the patient. The medicine is designed to accumulate in cancer cells while being quickly cleared from normal tissues in the body. The boron medicine remains inert until it is irradiated at the site of the tumor with safe, low-energy neutrons, releasing alpha particles that can destroy cancerous cells. BNCT may also have applications in treating other diseases. Currently there are 16 BNCT clinics worldwide, primarily in Asia and Europe. About Neutron Therapeutics Neutron Therapeutics is the leading provider of accelerator-based boron neutron capture therapy (BNCT) systems for use in targeted radiation therapy of solid tumors. Neutron Therapeutics’ flagship product, the nuBeam® therapy platform, is a compact, in-hospital neutron source designed to replace legacy nuclear reactors for BNCT. The nuBeam® system offers a higher neutron flux than competing systems and is the only BNCT system to adhere to all International Atomic Energy Agency standards. About Aviko Radiopharmaceuticals Aviko Radiopharmaceuticals is a privately held biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT) to treat a wide variety of cancers. Aviko’s innovative compounds are designed to improve the efficacy of BNCT by targeting and delivering boron to cancer cells with precision. Together with their partners, Aviko is advancing BNCT as a safe, efficacious and convenient treatment modality for patients. Founded by Deerfield Management, Aviko is based at Cure., a healthcare innovation campus in New York City. Follow Aviko on LinkedIn and Twitter. About Deerfield Management Deerfield is an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas, and technology in bold, collaborative and inclusive ways. For more information, please visit .